RESUMEN
PURPOSE@#The National Cancer Institute is the only referral centre in Malaysia that provides â¶â¸Ga-DOTA-peptide imaging. The purpose of this study is to determine the impact of â¶â¸Ga-DOTA-peptide PET/CT on the management of gastrointestinal neuroendocrine tumours (GI-NET).@*MATERIALS AND METHODS@#A cross-sectional study was performed to review the impact of â¶â¸Ga-DOTA-peptide (â¶â¸Ga-DOTATATE or â¶â¸Ga-DOTATOC) PET/CT on patients with biopsy-proven GI-NET between January 2011 and December 2015. Suspected NET was excluded. Demographic data, tumoral characteristics, change of disease stage, pre-PET intended management and post-PET management were evaluated.@*RESULTS@#Over a 5-year period, 82 studies of â¶â¸Ga-DOTA-peptide PET/CT were performed on 44 GI-NET patients. The most common primary site was the rectum (50.0%) followed by the small bowel, stomach and colon. Using WHO 2010 grading, 40.9%of patients had low-grade (G1) tumour, 22.7% intermediate (G2) and 4.5% high (G3). Of ten patients scheduled for pre-operative staging, â¶â¸Ga-DOTA-peptide PET/CT only led to therapeutic change in three patients. Furthermore, false-negative results of â¶â¸Ga-DOTA-peptide PET/CT were reported in one patient after surgical confirmation. However, therapeutic changes were seen in 20/36 patients (55.6%) scheduled for post-surgical restaging or assessment of somatostatin analogue (SSA) eligibility. When â¶â¸Ga-DOTApeptide PET/CT was used for monitoring disease progress during systemic treatment (sandostatin, chemotherapy, everolimus and PRRT) in metastatic disease, impact on management modification was seen in 19/36 patients (52.8%), of which 84.2% had inter-modality change (switch to everolimus, chemotherapy or PRRT) and 15.8% had intra-modality change (increased SSA dosage).@*CONCLUSIONS@#â¶â¸Ga-DOTA-peptide PET/CT has a significant impact on management decisions in GI-NET patients as it can provide additional information on occult metastasis/equivocal lesions and supply the clinician an opportunity to select patients for targeted therapy.
RESUMEN
carcinoma has been reclassified as non-invasive follicularthyroid neoplasm with papillary-like nuclear features (NIFTP)to emphasize the benign nature of this entity. In ourinstitution, we have assessed 455 patients treated withradioiodine ablation for differentiated thyroid carcinoma and20 of them were retrospectively found to fulfill the newNIFTP criteria. There was no evidence of metastasis on postradioiodine whole body scans for NIFTP cases and thesepatients were in remission subsequently. The benignfeatures of these patients’ whole body scans and goodclinical outcome following treatment further support NIFTPas a low risk thyroid neoplasm.
RESUMEN
PURPOSE: The National Cancer Institute is the only referral centre in Malaysia that provides ⁶⁸Ga-DOTA-peptide imaging. The purpose of this study is to determine the impact of ⁶⁸Ga-DOTA-peptide PET/CT on the management of gastrointestinal neuroendocrine tumours (GI-NET).MATERIALS AND METHODS: A cross-sectional study was performed to review the impact of ⁶⁸Ga-DOTA-peptide (⁶⁸Ga-DOTATATE or ⁶⁸Ga-DOTATOC) PET/CT on patients with biopsy-proven GI-NET between January 2011 and December 2015. Suspected NET was excluded. Demographic data, tumoral characteristics, change of disease stage, pre-PET intended management and post-PET management were evaluated.RESULTS: Over a 5-year period, 82 studies of ⁶⁸Ga-DOTA-peptide PET/CT were performed on 44 GI-NET patients. The most common primary site was the rectum (50.0%) followed by the small bowel, stomach and colon. Using WHO 2010 grading, 40.9%of patients had low-grade (G1) tumour, 22.7% intermediate (G2) and 4.5% high (G3). Of ten patients scheduled for pre-operative staging, ⁶⁸Ga-DOTA-peptide PET/CT only led to therapeutic change in three patients. Furthermore, false-negative results of ⁶⁸Ga-DOTA-peptide PET/CT were reported in one patient after surgical confirmation. However, therapeutic changes were seen in 20/36 patients (55.6%) scheduled for post-surgical restaging or assessment of somatostatin analogue (SSA) eligibility. When ⁶⁸Ga-DOTApeptide PET/CT was used for monitoring disease progress during systemic treatment (sandostatin, chemotherapy, everolimus and PRRT) in metastatic disease, impact on management modification was seen in 19/36 patients (52.8%), of which 84.2% had inter-modality change (switch to everolimus, chemotherapy or PRRT) and 15.8% had intra-modality change (increased SSA dosage).CONCLUSIONS: ⁶⁸Ga-DOTA-peptide PET/CT has a significant impact on management decisions in GI-NET patients as it can provide additional information on occult metastasis/equivocal lesions and supply the clinician an opportunity to select patients for targeted therapy.
Asunto(s)
Humanos , Colon , Estudios Transversales , Quimioterapia , Everolimus , Malasia , Tomografía Computarizada por Tomografía de Emisión de Positrones , Recto , Derivación y Consulta , Somatostatina , EstómagoRESUMEN
Objective[s]: The present study aimed to evaluate the role of pre-therapeutic 18fluorine-fluorodeoxyglucose positron emission tomography-computed tomography [[18]F-FDG PET-CT] and maximum standardized uptake value [SUV[max]] in guiding the treatment strategy and predicting the prognosis of esophageal carcinoma, using the survival data of the patients
Methods: The present retrospective, cohort study was performed on 40 consecutive patients with esophageal carcinoma [confirmed by endoscopic biopsy], who underwent pre-operative [18]F-FDG PET-CT staging between January 2009 and June 2014. All the patients underwent contrast-enhanced CT and non-contrasted [18]F-FDG PET-CT evaluations. The patients were followed-up over 12 months to assess the changes in therapeutic strategies. Survival analysis was done considering the primary tumor SUV[max], using the Kaplan-Meier product-limit method
Results: In a total of 40 patients, [18]F-FDG PET-CT scan led to changes in disease stage in 26[65.0%] cases, with upstaging and downstaging reported in 10 [25.0%] and 16[40.0%] patients, respectively. The management strategy changed from palliative to curative in 10 out of 24 patients and from curative to palliative in 7 out of 16 cases. Based on the [18]F-FDG PET-CT scan alone, the median survival of patients in the palliative group was 4.0[95 % CI 3.0-5.0] months, whereas the median survival in the curative group has not been reached, based on the 12-month follow-up. Selection of treatment strategy on the basis of [18]F-FDG PET/CT alone was significantly associated with the survival outcomes at nine months [P=0.03] and marginally significant at 12 months [P=0.05]. On the basis of SUV[max], the relation between survival and SUV[max]was not statistically significant
Conclusion: [18]F-FDG PET/CT scan had a significant impact on stage stratification and subsequently, selection of a stage-specific treatment approach and the overall survival outcome in patients with esophageal carcinoma. However, pre-treatment SUV[max]failed to stablish its usefulness in the assessment of patient prognosis and survival outcome